This book addresses the latest advances in viral and non-viral vectors, novel targets and methods for the treatment of autoimmune and inflammatory disease with a main focus in pre-clinical testing with up to date clinical trials. The first section of the book deals with current research approaches f
Gene Therapy for Autoimmune and Inflammatory Diseases
β Scribed by Florence Apparailly, Paul Peter Tak (auth.), Yuti Chernajovsky, Paul D. Robbins (eds.)
- Publisher
- Springer Basel
- Year
- 2010
- Tongue
- English
- Leaves
- 249
- Series
- Milestones in Drug Therapy
- Edition
- 1
- Category
- Library
No coin nor oath required. For personal study only.
β¦ Synopsis
In this monograph about gene therapy of autoimmune and inflammatory d- orders we have gathered international experts and leaders from different fields to review the state of the art advances on topics ranging from disease entities to vectors and engineered cells. The different approaches described in each chapter take into consideration the biomedical knowledge of these diseases and address the complexities of delivering long-term genetic interventions. Gene therapy also serves as a testing ground for new therapeutic entities and helps provide proof of principle for their potential therapeutic role in animal models of disease. Scaling up from mice to men still remains an important h- dle not only from the quantitative point of view, but also for currently unknown and unexpected secondary effects of the vector or the transgene. Some of these approaches have already been tested in the clinic, but much more needs to be done to understand the human conditions treated and the n- ural history of their pathology. We are indebted to the secretarial assistance of Ms. Lin Wells (Bone and Joint Research Unit, London, UK) and the help of Hans Detlef KlΓΌber for his help in getting this book published. We hope this book will be of interest to c- nicians and scientists and inspiring to students of the subject who will use their own ingenuity and knowledge to further forward this discipline into clinical use.
β¦ Table of Contents
Front Matter....Pages I-XI
Gene therapy for arthritis....Pages 1-18
Gene therapy for the treatment of inflammatory bowel disease....Pages 19-37
Gene therapy for diabetes....Pages 39-46
Gene therapy for cystic fibrosis lung disease....Pages 47-64
Gene therapy of multiple sclerosis....Pages 65-78
Gene therapy for myositis....Pages 79-90
Gene therapy for osteoarthritis....Pages 91-112
Gene therapy: SjΓΆgrenβs syndrome....Pages 113-125
Disease mechanisms, genetic susceptibility and therapeutic approaches in lupus disease....Pages 127-146
Regulated promoters....Pages 147-159
Development of AAV vectors for the therapy of autoimmune and inflammatory diseases....Pages 161-180
Delivery and application of plasmid DNA in arthritis gene therapy....Pages 181-192
Helper-dependent adenoviral vectors....Pages 193-207
Cells as carriers of gene therapy....Pages 209-222
Perspectives for the future developments of gene therapy for autoimmune and inflammatory therapy....Pages 223-231
Back Matter....Pages 233-244
β¦ Subjects
Gene Therapy; Pharmacology/Toxicology; Immunology; Rheumatology; Molecular Medicine
π SIMILAR VOLUMES
<p><P>Autoimmune diseases are diverse and responsible for considerable morbidity. Their etiology remains largely unknown, and current therapy with anti-inflammatory drugs is prone to adverse effects, and rarely curative. New therapies with anti-cytokine antibodies or receptors are promising, but req
<p><span>Autoimmune diseases are diverse and responsible for considerable morbidity. Their etiology remains largely unknown, and current therapy with anti-inflammatory drugs is prone to adverse effects, and rarely curative. New therapies with anti-cytokine antibodies or receptors are promising, but
<p>Gene therapy for inflammatory diseases is a new , burgeoning field of medicine. Edited by the undisputed pioneers of this area of research, this volume is the first devoted to its topic. It contains thirteen chapters, each written by leaders in their respective fields, that summarize the state of
<p><p>As our understanding of immune mediated chronic inflammatory diseases (IMIDs) grows, it becomes more and more clear that these conditions result from the convergence of a multitude of pathogenic mechanisms whose relative individual contribution is different in different patient subsets.</p><p>
Autoimmune diseases are diverse and responsible for considerable morbidity. Their etiology remains largely unknown, and current therapy with anti-inflammatory drugs is prone to adverse effects, and rarely curative. New therapies with anti-cytokine antibodies or receptors are promising, but require f